{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:22:16Z","timestamp":1784672536916,"version":"3.55.0"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ganciclovir (GCV) and foscarnet (FOS) are the most commonly used antivirals for preemptive treatment of cytomegalovirus (CMV) viremia in recipients of allogeneic hematopoietic cell transplantation (alloHCT). The current literature indicates similar efficacy between these agents. Thus, the primary consideration for choice of initial anti\u2010CMV treatment is the safety profile, time period after alloHCT, and concern of myelosuppression or renal dysfunction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein, we retrospectively reviewed medical records of 124 alloHCT recipients who received GCV or FOS between April 27, 2014, and December 31, 2015, during the first year post\u2010transplant. Healthcare resource use included drug, hospitalization, home health, dialysis, and growth factor costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Total duration of therapy was longer in the GCV group (37\u00a0days vs 28\u00a0days, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.21) but hospitalization days were similar (9\u00a0days) in both groups. The total treatment cost was significantly lower in the GCV group ($38\u00a0100 vs $59\u00a0400, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Preemptive anti\u2010CMV therapy is associated with major healthcare resource costs, which were greater in patients who required FOS than those who were treated with GCV.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.13233","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T05:24:55Z","timestamp":1576473895000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-7621","authenticated-orcid":false,"given":"Jason","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Abella Ross","sequence":"additional","affiliation":[{"name":"Department of Pharmacy City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Tegtmeier","sequence":"additional","affiliation":[{"name":"Department of Quality, Risk and Regulatory Management City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Information Sciences City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Disease City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Zaia","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy City of Hope Duarte California"},{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana K","family":"Dickter","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Disease City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"Department of Clinical Translational Program Development City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Kriengkauykiat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Grady Health Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet S","family":"Dadwal","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Disease City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/4.6.1119"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.478"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679639"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ215"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-069294"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701302"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1159"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25574"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1649379"},{"key":"e_1_2_8_13_1","unstructured":"FoundationKF.Hospital adjusted expenses per inpatient day by ownership:http:\/\/kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day-by-ownership\/?currentTimeframe=0&selectedRows=%7B%22nested%22:%7B%22california%22:%7B%7D%7D%7D&sortModel=%7B%22colId%22:%22Location%22 %22sort%22:%22asc%22%7D"},{"key":"e_1_2_8_14_1","unstructured":"Medicare.Medicare and home infusion. National home infusionAssociation website. ; 2014:http:\/\/www.nhia.org\/resource\/legislative\/NHIAMHISOCAWhitePaper.cfm"},{"key":"e_1_2_8_15_1","unstructured":"Costs of ESRD.United States renal data systemwebsite; 2013:https:\/\/www.usrds.org\/2013\/view\/v2_11.aspx"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2854-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.02.010"},{"key":"e_1_2_8_18_1","unstructured":"Letermovir (Prevymis\u2122) (package insert).Whitehouse Station NJ: Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc.2017."}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.13233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.13233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:12:56Z","timestamp":1693818776000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.13233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/tid.13233"],"URL":"https:\/\/doi.org\/10.1111\/tid.13233","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,30]]},"assertion":[{"value":"2019-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13233"}}